Thursday, February 23, 2023
Glooko announced that they have entered into a partnering agreement with Sanofi to increase the support for people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform. SoloSmart is a single piece add-on connected device intended for use with SoloStar and DoubleStar insulin injection pens which records the insulin dose, date and time of injection and allows for visualisation of the data in the Glooko app, that patients can share with healthcare professionals for connected care in diabetes management. At this time, SoloSmart is not approved in the US.
This partnership represents the first substantial digital health collaboration between two companies. Glooko is the first global diabetes data management platform to launch with SoloSmart. This allows to further expand global reach aiming to provide best-in-class technologies benefiting the lives of people with diabetes.
The SoloSmart cap is currently undergoing integration with the Glooko platform and will gradually roll out across several countries starting later in 2023. The combined solution will be made available in English and local languages. As part of the global agreement, Glooko and Sanofi contemplate the option to further expand the launch of the combined technologies beyond the initial geographic scope.
